{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:59:20Z","timestamp":1791082760076,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health and Biology Area of Science and Technology Program of Yuncheng City","award":["YCKJYD-202413"],"award-info":[{"award-number":["YCKJYD-202413"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02761-3","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:08:25Z","timestamp":1747624105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-\u03b1-2b-based therapy: a multicenter pilot study"],"prefix":"10.1186","volume":"22","author":[{"given":"Li-Jun","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Qiu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Rong","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cun-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Xian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qi","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5471","authenticated-orcid":false,"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"28","key":"2761_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","volume":"67","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, Bulterys M. Access to treatment for hepatitis B virus Infection - Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10161","key":"2761_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"issue":"6","key":"2761_CR3","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"2761_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"2761_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"2","key":"2761_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the L. EASL. 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"9","key":"2761_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.cgh.2012.03.016","volume":"10","author":"CQ Pan","year":"2012","unstructured":"Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High rates of viral suppression after long-term Entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10(9):1047\u2013e10501041.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2761_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422\u201330.","journal-title":"Hepatology"},{"issue":"9865","key":"2761_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al. Regression of cirrhosis during treatment with Tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375.","journal-title":"Lancet"},{"issue":"3","key":"2761_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, et al. Tenofovir Alafenamide versus Tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2761_CR11","first-page":"649","volume":"11","author":"Z Liu","year":"2023","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, et al. 96-Week treatment of Tenofovir Amibufenamide and Tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol. 2023;11(3):649\u201360.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"2761_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and Meta-analysis. Gastroenterology. 2019;156(3):635\u2013e646639.","journal-title":"Gastroenterology"},{"issue":"7","key":"2761_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jvh.13283","volume":"27","author":"MA Fonseca","year":"2020","unstructured":"Fonseca MA, Ling JZJ, Al-Siyabi O, Co-Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. J Viral Hepat. 2020;27(7):650\u201362.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2761_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u201372.","journal-title":"Hepatol Int"},{"issue":"4","key":"2761_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5009\/gnl240023","volume":"18","author":"ASF Lok","year":"2024","unstructured":"Lok ASF. Toward a functional cure for hepatitis B. Gut Liver. 2024;18(4):593\u2013601.","journal-title":"Gut Liver"},{"key":"2761_CR16","doi-asserted-by":"crossref","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F, Faculty E-AHTEC. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J Hepatol. 2020; 72(3):539\u2013557.","DOI":"10.1016\/j.jhep.2019.11.003"},{"issue":"1","key":"2761_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","volume":"18","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J. 2021;18(1):114.","journal-title":"Virol J"},{"issue":"1","key":"2761_CR18","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.jhep.2023.11.018","volume":"81","author":"M Anderson","year":"2024","unstructured":"Anderson M, Holzmayer V, Stec M, Cloherty G, Lim SG. Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: considerations for new and existing therapies. J Hepatol. 2024;81(1):e24\u20135.","journal-title":"J Hepatol"},{"issue":"4","key":"2761_CR19","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s40121-021-00511-w","volume":"10","author":"Y Huang","year":"2021","unstructured":"Huang Y, Qi M, Liao C, Xun J, Zou J, Huang H, Long LY, Chen J, Fan X, Chen R. Analysis of the efficacy and safety of pegylated Interferon-alpha2b treatment in inactive hepatitis B surface antigen carriers. Infect Dis Ther. 2021;10(4):2323\u201331.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"2761_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/liv.14897","volume":"41","author":"F Wu","year":"2021","unstructured":"Wu F, Lu R, Liu Y, Wang Y, Tian Y, Li Y, Li M, Wang W, Zhang X, Jia X, Dang S. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int. 2021;41(9):2032\u201345.","journal-title":"Liver Int"},{"key":"2761_CR21","doi-asserted-by":"publisher","first-page":"1332232","DOI":"10.3389\/fcimb.2023.1332232","volume":"13","author":"C Wen","year":"2023","unstructured":"Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, Zhou Z, Shi X. Clinical cure induced by pegylated interferon alpha-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study. Front Cell Infect Microbiol. 2023;13:1332232.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"2761_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/MEG.0000000000002627","volume":"35","author":"H Ning","year":"2023","unstructured":"Ning H, Li K, Peng Z, Jin H, Zhao H, Shang J. The efficacy and safety of pegylated interferon alpha-2b-based immunotherapy for inactive hepatitis B surface antigen carriers. Eur J Gastroenterol Hepatol. 2023;35(10):1216\u201323.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2761_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29(3):605\u201322.","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"2761_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/apt.17670","volume":"58","author":"N Gao","year":"2023","unstructured":"Gao N, Guan G, Xu G, Wu H, Xie C, Mo Z, Deng H, Xiao S, Deng Z, Peng L, et al. Integrated HBV DNA and CccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy. Aliment Pharmacol Ther. 2023;58(10):1086\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2761_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26(10):1146\u201355.","journal-title":"J Viral Hepat"},{"key":"2761_CR26","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.3389\/fmicb.2022.980250","volume":"13","author":"MJ Peng","year":"2022","unstructured":"Peng MJ, Guo XQ, Zhang WL, Chen J, Kang W, Yang XF, Guo Y, Zhang Y. Effect of pegylated interferon-alpha2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience. Front Microbiol. 2022;13:980250.","journal-title":"Front Microbiol"},{"key":"2761_CR27","doi-asserted-by":"publisher","first-page":"1489671","DOI":"10.3389\/fmed.2024.1489671","volume":"11","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y. Safety and efficacy of 48-week pegylated interferon-alpha-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Front Med (Lausanne). 2024;11:1489671.","journal-title":"Front Med (Lausanne)"},{"issue":"44","key":"2761_CR28","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3748\/wjg.v30.i44.4725","volume":"30","author":"R Lu","year":"2024","unstructured":"Lu R, Zhang M, Liu ZH, Hao M, Tian Y, Li M, Wu FP, Wang WJ, Shi JJ, Zhang X, et al. Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. World J Gastroenterol. 2024;30(44):4725\u201337.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2761_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","volume":"37","author":"M Li","year":"2022","unstructured":"Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in hbeag positive chronic hepatitis B patients. Virol Sin. 2022;37(3):390\u20137.","journal-title":"Virol Sin"},{"issue":"14","key":"2761_CR30","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00018-018-2753-8","volume":"75","author":"W Wang","year":"2018","unstructured":"Wang W, Bian H, Li F, Li X, Zhang D, Sun S, Song S, Zhu Q, Ren W, Qin C, Qi J. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. Cell Mol Life Sci. 2018;75(14):2627\u201341.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"2761_CR31","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1038\/s41423-021-00769-7","volume":"18","author":"X Xie","year":"2021","unstructured":"Xie X, Luo J, Broering R, Zhu D, Zhou W, Lu M, Zheng X, Dittmer U, Yang D, Liu J. HBeAg induces liver sinusoidal endothelial cell activation to promote intrahepatic CD8 T cell immunity and HBV clearance. Cell Mol Immunol. 2021;18(11):2572\u20134.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2761_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.virol.2009.11.007","volume":"397","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Lian JQ, Huang CX, Wang JP, Wei X, Nan XP, Yu HT, Jiang LL, Wang XQ, Zhuang Y, et al. Overexpression of Toll-like receptor 2\/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection. Virology. 2010;397(1):34\u201342.","journal-title":"Virology"},{"issue":"10","key":"2761_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jvh.13734","volume":"29","author":"N Gao","year":"2022","unstructured":"Gao N, Yu H, Zhang J, Mo Z, Chu J, Xie C, Peng L, Gao Z. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy. J Viral Hepat. 2022;29(10):899\u2013907.","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"2761_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat. 2019;26(Suppl 1):32\u201341.","journal-title":"J Viral Hepat"},{"issue":"5","key":"2761_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","volume":"151","author":"WS Mason","year":"2016","unstructured":"Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S, Quaglia A, Bertoletti A, Kennedy PT. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151(5):986\u2013e998984.","journal-title":"Gastroenterology"},{"issue":"4","key":"2761_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","volume":"65","author":"A Boyd","year":"2016","unstructured":"Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under Tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65(4):683\u201391.","journal-title":"J Hepatol"},{"issue":"2","key":"2761_CR37","first-page":"314","volume":"11","author":"W Gan","year":"2023","unstructured":"Gan W, Gao N, Gu L, Mo Z, Pang X, Lei Z, Gao Z. Reduction in intrahepatic CccDNA and integration of HBV in chronic hepatitis B patients with a functional cure. J Clin Transl Hepatol. 2023;11(2):314\u201322.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"2761_CR38","doi-asserted-by":"publisher","first-page":"e184243","DOI":"10.1172\/JCI184243","volume":"135","author":"M Taddese","year":"2025","unstructured":"Taddese M, Grudda T, Belluccini G, Anderson M, Cloherty G, Hwang HS, Mani M, Lo CM, Esrig N, Sulkowski MS, et al. Transcription of hepatitis B surface antigen shifts from CccDNA to integrated HBV DNA during treatment. J Clin Invest. 2025;135(6):e184243.","journal-title":"J Clin Invest"},{"key":"2761_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","volume":"105","author":"S Lou","year":"2018","unstructured":"Lou S, Taylor R, Pearce S, Kuhns M, Leary T. An ultra-sensitive Abbott ARCHITECT((R)) assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol. 2018;105:18\u201325.","journal-title":"J Clin Virol"},{"issue":"2","key":"2761_CR40","doi-asserted-by":"publisher","first-page":"e0220421","DOI":"10.1128\/jcm.02204-21","volume":"60","author":"DK Wong","year":"2022","unstructured":"Wong DK, Chen C, Mak LY, Fung J, Seto WK, Yuen MF. Detection of the hepatitis B surface antigen in patients with occult hepatitis B by use of an assay with enhanced sensitivity. J Clin Microbiol. 2022;60(2):e0220421.","journal-title":"J Clin Microbiol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02761-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:08:28Z","timestamp":1747624108000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02761-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02761-3","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Tangdu Hospital (202301-06), Yuncheng Central Hospital (YXLL2024072), and Air Force Hospital of Southern Theatre Command (2024-01). The Ethics Committees waived the requirement of written informed consent for participation from the participants or the participants\u2019 legal guardians\/next of kin because this was a retrospective study, and only characteristics and laboratory indicators were collected. We used an anonymized database for all analyses, and all potentially identifying variables were removed. The study involving human participants was conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This trial is a part of ZhuFeng Project (The Clinical Cure Project of Chronic Hepatitis B in China; ClinicalTrials.gov, identifier: NCT04035837) and a part of E-Cure Study (Real World Study of Peginterferon \u03b1-2b Treatment for Inactive Chronic Hepatitis B Patients; ClinicalTrials.gov, identifier NCT05182463).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}